A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc.
Eli Lilly and Company
Plexium, Inc.
Rondo Therapeutics
Novartis
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Carisma Therapeutics Inc
Pfizer
Advaxis, Inc.
AO GENERIUM
Adaptimmune
H. Lee Moffitt Cancer Center and Research Institute
Blueprint Medicines Corporation
Novartis
Checkpoint Therapeutics, Inc.
Novartis
KitovPharma
University of Rochester
National Institutes of Health Clinical Center (CC)
Santa Maria Biotherapeutics
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
University of Arkansas